[A transdermal form of combined hormonal contraceptives (EVRA)].
OBJECTIVE
To present a review of a novel transdermal contraceptive patch containing norelgestromin (150 micrograms/d) and ethinylestradiol (20 micrograms/d).


METHODS
Review article.


METHODS
Department of Gynecology and Obstetric, 1st Medical Faculty and General Faculty Hospital, Prague.


RESULTS
The contraceptive patch exhibits favourable pharmakokinetic profile, maintaining efficacious serum hormone concentrations under varying conditions and without peaks and through characteristic of oral dosing. Efficacy, cycle control, tolerability and side effect profile were comparable to an established oral contraceptive. Compliance with the weekly administered contraceptive patch was significantly better than with an oral contraceptive. The reliability of adhesion of the patch is very high and consistent even under varying conditions (heat, humidity, exercise).
Fanta
M
M
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze.
D000279:Administration, Cutaneous; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005003:Ethisterone / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000031:analogs & derivatives; D010091:Oximes
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005003:Ethisterone; C449219:norelgestromin